Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 101 to 150 of 444 results for stroke

  1. For people after stroke with communication difficulties, what is the optimal tool for assessing fatigue?

    Recommendation ID NG236/3 Question For people after stroke with communication difficulties, what is the optimal tool for assessing...

  2. Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management (NG228)

    This guideline covers diagnosing and treating an aneurysmal (caused by a ruptured aneurysm) subarachnoid haemorrhage and its complications. It provides recommendations to improve diagnosis and ensure that the most effective treatments are offered. It includes guidance on follow-up care and information for people (aged 16 and over) who have had an aneurysmal subarachnoid haemorrhage, their families and carers.

  3. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (DG14)

    Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available

  4. Acute upper gastrointestinal bleeding in over 16s: management (CG141)

    This guideline covers how upper gastrointestinal bleeding can be effectively managed in adults and young people aged 16 years and older. It aims to identify which diagnostic and therapeutic steps are useful so hospitals can develop a structure in which clinical teams can deliver an optimum service for people who develop this condition.

  5. Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

    Evidence-based recommendations on edoxaban (Lixiana) for treating deep vein thrombosis and pulmonary embolism in adults and preventing them happening again.

  6. Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190

    Awaiting development [GID-TA11283] Expected publication date: TBC

  7. What is the clinical and cost effectiveness of more intensive cognitive and psychological therapy compared to usual care for people after a stroke?

    cognitive and psychological therapy compared to usual care for people after a stroke? Any explanatory notes(if applicable) For a short...

  8. Artificial intelligence for analysing CT brain scans (MIB207)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .

  9. Peripheral arterial disease (QS52)

    This quality standard covers diagnosing and managing lower limb peripheral arterial disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  10. ReStore Soft Exo-Suit for gait rehabilitation (MIB239)

    NICE has developed a medtech innovation briefing (MIB) on ReStore Soft Exo-Suit for gait rehabilitation .

  11. Board

    Our board sets out our strategic priorities and policies.

  12. What is the clinical and cost effectiveness of delivering rehabilitation for 7 days a week compared to 5 days a week for people after a stroke?

    rehabilitation for 7 days a week compared to 5 days a week for people after a stroke? Any explanatory notes(if applicable) For a short...

  13. Carotid artery stent placement for symptomatic extracranial carotid stenosis (IPG389)

    Evidence-based recommendations on carotid artery stent placement for symptomatic extracranial carotid stenosis. This involves using a metal mesh called a stent to widen the narrowed carotid artery.

  14. Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.

  15. Board, executive team and senior leaders interests register

    (non-executive director) Bayer acute stroke trial consultancy. (remunerated – paid to employer)CSL Behring Consultancy advice for...

  16. Board, executive team and senior leaders interests register

    (non-executive director) Bayer acute stroke trial consultancy. (remunerated – paid to employer)CSL Behring Consultancy advice for...

  17. Board, executive team and senior leaders interests register

    (non-executive director) Bayer acute stroke trial consultancy. (remunerated – paid to employer)CSL Behring Consultancy advice for...

  18. NICE impact cardiovascular disease prevention

    Find out more about the progress made in implementing NICE guidance on cardiovascular disease prevention

  19. Avoidance of aspiration pneumonia: Does the withdrawal of oral liquids or the use of modified (thickened) oral fluids prevent the development of aspiration pneumonia after an acute stroke?

    pneumonia after an acute stroke? Any explanatory notes(if applicable) People with dysphagia after an acute stroke are at...

  20. Extracranial to intracranial bypass for intracranial atherosclerosis (IPG596)

    Evidence-based recommendations on extracranial to intracranial bypass for intracranial atherosclerosis. This involves joining a blood vessel from outside the skull to one inside the skull to bypass a narrowed or partially blocked vessel.

  21. For people with different causes of shoulder pain after stroke, what is the clinical and cost effectiveness of interventions in reducing pain?

    Question For people with different causes of shoulder pain after stroke, what is the clinical and cost effectiveness of interventions...

  22. Safety and efficacy of carotid stenting: What is the safety and efficacy of carotid stenting compared with carotid endarterectomy when these procedures are carried out within 2 weeks of TIA or recovered stroke?

    when these procedures are carried out within 2 weeks of TIA or recovered stroke? Any explanatory notes(if applicable) Carotid stenting...

  23. Pharyngeal electrical stimulation for neurogenic dysphagia (IPG781)

    Evidence-based recommendations on pharyngeal electrical stimulation for neurogenic dysphagia. This involves passing a catheter through the nose and into the throat where it is used to deliver small amounts of electrical current. The current travels from the throat to the brain and stimulates the areas involved in swallowing.

  24. Endovascular stent insertion for intracranial atherosclerotic disease (IPG429)

    Evidence-based recommendations on endovascular stent insertion for intracranial atherosclerotic disease. This involves inflating a balloon catheter inserted into an artery in the arm or leg, and positioning a stent in the narrowing to maintain improved blood flow.

  25. Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)

    Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention for treating acute coronary syndromes in adults.

  26. Thoracoscopic exclusion of the left atrial appendage (with or without surgical ablation) for non-valvular atrial fibrillation for the prevention of thromboembolism (IPG400)

    Evidence-based recommendations on thoracoscopic exclusion of the left atrial appendage in atrial fibrillation (with or without other cardiac surgery) for the prevention of thromboembolism. This involves inserting a camera and instruments through small cuts in the chest and closing the left atrial appendage.

  27. Overprescribing of rivaroxaban in non-atrial fibrillation patients in primary care

    are detailed. Patients who were on rivaroxaban for lifelong prevention of stroke and systemic embolism in association with atrial...

  28. Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI (IPG650)

    Evidence-based recommendations on percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI in adults. This involves placing a device inside an artery near the heart.

  29. Atrial Fibrillation (AF) Holistic Care Pathway

    under a more unified programme. There was a realisation that AF related stroke was a major problem globally and locally and any measures...

  30. What is the clinical and cost effectiveness of computer-based tools to treat problems with speech (dysarthria) and all domains of language (aphasia) for people with communication difficulties after stroke?

    domains of language (aphasia) for people with communication difficulties after stroke? Any explanatory notes(if applicable) For a short...

  31. Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis (IPG777)

    Evidence-based recommendations on percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis. This involves using a wire mesh tube called a stent to widen the narrowed carotid artery.

  32. Sickle cell disease: managing acute painful episodes in hospital (CG143)

    This guideline covers managing acute painful sickle cell episodes in children, young people and adults who present at hospital, from presentation until when they are discharged. It aims to reduce variation in how acute episodes are managed in hospital, focusing on effective, prompt and safe pain relief.

  33. ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)

    NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot

  34. Migalastat for treating Fabry disease (HST4)

    Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16.

  35. Using NICE guidance in social work

    A range of fictional scenarios which show how NICE's guidelines and quality standards could be used by social workers in different settings.

  36. Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events (IPG472)

    Evidence-based recommendations on percutaneous closure of the patent foramen ovale for the prevention of cerebral embolic stroke. This involves placing a small device into the heart to close the hole.

  37. Diabetes: statins for secondary prevention of CVD (IND184)

    This indicator covers the percentage of patients with diabetes and a history of cardiovascular disease (excluding a history of haemorrhagic stroke) who are currently treated with a statin. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM163

  38. Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]

    In development [GID-TA11512] Expected publication date: TBC

  39. Weight management: lifestyle services for overweight or obese adults (PH53)

    This guideline covers multi-component lifestyle weight management services including programmes, courses, clubs or groups provided by the public, private and voluntary sector. The aim is to help people lose weight and become more physically active to reduce the risk of diseases associated with obesity. This includes coronary heart disease, stroke, type 2 diabetes and various cancers.

  40. Hypertension: Improving blood pressure management in primary care

    and the national data shows an increased rate of hospital admissions for stroke. Hypertension is therefore a particular issue for...

  41. Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism (IPG349)

    Evidence-based recommendations on percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism. This involves using a special device to block the mouth of the left atrial appendage and stop the blood clot from getting into the bloodstream.

  42. Colorectal cancer . Patient decision aid on Lynch syndrome: should I take aspirin to reduce my chance of getting bowel cancer?

    people in 10,000 do not). Aspirin can also make a type of stroke known as haemorrhagic stroke (bleeding inside the brain)...

  43. Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis (MIB93)

    NICE has developed a medtech innovation briefing (MIB) on the Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis .

  44. Faecal incontinence in adults: management (CG49)

    This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.

  45. Cardiovascular disease prevention: cholesterol treatment target (secondary prevention) (IND268)

    This indicator covers the percentage of patients with CVD in whom the last recorded LDL cholesterol level (measured in the preceding 12 months) is 2.0 mmol per litre or less, or last recorded non-HDL cholesterol level (measured in the preceding 12 months) is 2.6 mmol per litre or less, if LDL cholesterol is not recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM252

  46. Diabetes: complications (IND9)

    This indicator covers the proportion of adults with a diagnosis of diabetes who have a recording of myocardial infarction (MI), stroke and/or end stage kidney disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG12

  47. Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults (IPG634)

    Evidence-based recommendations on transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults. This involves electrically stimulating nerves in the throat or neck, while the person swallows. The aim is to strengthen the muscles involved in swallowing.

  48. Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)

    This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.

  49. Air pollution: outdoor air quality and health (QS181)

    This quality standard covers road-traffic-related air pollution and its impact on health. It describes high-quality actions in priority areas for improvement.